Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 11;32(4):225.
doi: 10.3390/curroncol32040225.

A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening

Diedron Lewis  1 , Laura Jiménez  2 , Kelvin K Chan  3 , Susan Horton  4 , William W L Wong  1
Affiliations

A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening

Diedron Lewis et al. Curr Oncol. .

Abstract

Background: Pancreatic cancer (PC) is among the deadliest types of cancer globally. While early detection helps avert adverse outcomes, screening is only recommended for individuals at high risk, specifically those with familial and/or genetic predispositions. The objectives of this study are to systematically review primary studies on the cost-effectiveness of PC screening and to identify the critical factors that influence cost-effectiveness.

Methods: This systematic review was performed using PRISMA guidelines. Economic evaluation studies on PC screening were identified from searches on the SCOPUS and PubMed databases. The quality of reporting of the selected articles was assessed according to CHEERS 2022. Using predefined inclusion and exclusion criteria, two reviewers conducted the title-abstract review, full-text review, and data extraction to select relevant articles. The authors' consensus was used to settle disagreements. The primary outcome was the incremental cost-effectiveness ratio, measured by cost per quality-adjusted life year and cost per life year saved.

Results: Nine studies were selected for the final review. Most studies demonstrated that one-time screening for PC among high-risk individuals was cost-effective compared with no screening, while others found annual screening to also be cost-effective. High-risk was generally defined as having a >5% lifetime risk of PC and included individuals with either familial pancreatic cancer (FPC) or genetic susceptibility syndromes such as Peutz-Jeghers Syndrome, hereditary pancreatitis, hereditary non-polypoid colorectal cancer syndrome, familial adenomatous polyposis, and BRCA2 mutations. Individuals with new-onset diabetes (NOD) were also considered high-risk. Screening using mainly endoscopic ultrasound was cost-effective among FPC individuals and those with genetic syndromes. Risk-based screening was also cost-effective among patients with NOD.

Conclusion: Screening for PC is cost-effective among selected high-risk individuals. However, cost-effectiveness depends on epidemiological factors, cost, the diagnostic performance of screening tools, and the overall design of studies.

Keywords: cost-effectiveness; pancreatic cancer screening; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA diagram of the selection process of the included studies [31].
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ferlay J., Ervik M., Lam F., Laversanne M., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I. Bray Global Cancer Observatory: Cancer Today. [(accessed on 17 February 2024)]. Available online: https://gco.iarc.who.int/today.
    1. Kenner B.J., Chari S.T., Maitra A., Srivastava S., Cleeter D.F., Go V.L.W., Rothschild L.J., Goldberg A.E. Early Detection of Pancreatic Cancer—A Defined Future Using Lessons from Other Cancers. Pancreas. 2016;45:1073–1079. doi: 10.1097/MPA.0000000000000701. - DOI - PMC - PubMed
    1. Bjerregaard J.K., Mortensen M.B., Schønnemann K.R., Pfeiffer P. Characteristics, Therapy and Outcome in an Unselected and Prospectively Registered Cohort of Pancreatic Cancer Patients. Eur. J. Cancer. 2013;49:98–105. doi: 10.1016/j.ejca.2012.07.017. - DOI - PubMed
    1. Huang L., Jansen L., Balavarca Y., Molina-Montes E., Babaei M., van der Geest L., Lemmens V., Van Eycken L., De Schutter H., Johannesen T.B., et al. Resection of Pancreatic Cancer in Europe and USA: An International Large-Scale Study Highlighting Large Variations. Gut. 2019;68:130–139. doi: 10.1136/gutjnl-2017-314828. - DOI - PubMed
    1. National Cancer Institute SEER Cancer Stat Facts: Pancreatic Cancer. [(accessed on 22 September 2024)]; Available online: https://seer.cancer.gov/statfacts/html/pancreas.html.

Publication types

MeSH terms

LinkOut - more resources